Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Al[18F]F-NOTA-folate is a positron emission tomography (PET) radiopharmaceutical tracer designed to target the folate receptor, specifically the beta isoform (FR-β) expressed on activated macrophages. Developed by researchers at Turku University Hospital, the tracer utilizes an aluminum-fluoride-18 (Al[18F]F) complex chelated by a NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) moiety conjugated to a folate ligand. It is primarily being investigated for the non-invasive detection and monitoring of inflammatory conditions characterized by macrophage infiltration, such as cardiac sarcoidosis and infective endocarditis. By binding to FR-β on activated macrophages rather than relying on metabolic activity (like FDG), it aims to provide higher specificity in imaging myocardial inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Al[18F]F-NOTA-folate.